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Background: Pulmonary arterial hypertension (PAH) is a rare disease characterized by a pro-proliferative endothelial cell phenotype, vascular 
inflammation and pulmonary vessel remodeling culminating in right ventricular failure and ultimately death. Mutations in bone morphogenetic 
protein type II receptor (BMPR2), a member of the TGF-β superfamily, have been identified in the majority of patients with heritable PAH. Loss 
of normal BMPR2 function has been implicated in the abnormal endothelial cell growth and the formation of plexiform lesions characteristic of 
advanced PAH. We hypothesized that BMPR2 deficiency could alter the interactions of cytoskeletal scaffolding proteins and the RAF-ERK1/2-AP1 
signaling pathway, leading to its dysregulated activation.
Results: BMPR2 siRNA gene silencing in pulmonary artery endothelial cells (PAEC) significantly activated ERK1/2 signaling. Microarray analysis 
found that BMPR2 knockdown (KD) suppressed Sprouty1, an inhibitor of ERK1/2 signaling and induced RAF-1, an upstream activator of ERK1/2. 
Western blotting confirmed that BMPR2 KD increased the expression of all three RAF family members, RAF-1, A-RAF and B-RAF. In addition to total 
protein, phosphorylated RAF, an activating event, was increased by BMPR2 silencing across all three family members. Inhibitors of MEK1/2 and RAF 
proteins reduced the activation of ERK1/2 and the expression of FRA1, an AP1 family member and target of ERK1/2 signaling. Notably, scaffolding 
proteins are known to regulate the intensity, amplitude, and spatial specificity of ERK1/2 signaling. Receptor for activated C-kinase (RACK1) has 
been shown to interact with BMPR2 and co-immunoprecipitation confirmed the interaction between BMPR2 and RACK and among RACK1, A-RAF and 
B-RAF proteins in PAECs.
conclusions: Activation of the RAF-ERK1/2-AP1 signaling pathway by BMPR2 silencing is reinforced by downstream induction and suppression of 
regulatory molecules. In addition, BMPR2 directly interacts with upstream partners of RAF-ERK1/2 and its loss may alter their function. Disordered 
RAF-ERK1/2-AP1 signaling may contribute to the vascular remodeling characteristic of PAH.
